342417-01-0

Basic information

• Product Name: 3-PYRIDINECARBOXAMIDE, 4-(2-METHYLPHENYL)-6-(4-METHYL-1-PIPERAZINYL)-
• Synonyms: 6-(4-METHYLPIPERAZIN-1-YL)-4-O-TOLYLNICOTINAMIDE;4-(2-Methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinecarboxamide;6-(4-Methylpiperazin-1-yl)-4-(2-methylphenyl)nicotinamide;4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridine-3-carboxamide;3-PYRIDINECARBOXAMIDE, 4-(2-METHYLPHENYL)-6-(4-METHYL-1-PIPERAZINYL)-C32;4-(2-methylphenyl)-6-(4-methylpiperazinyl)-3-pyridinecarboxamide;3-PYRIDINECARBOXAMIDE, 4-(2-METHYLPHENYL)-6-(4-METHYL-1-PIPERAZINYL)-
• CAS NO: 342417-01-0
• Molecular Formula: C₁₈H₂₂N₄O
• Molecular Weight: 310.39
• Mol File: 342417-01-0.mol
• Article Data: 9

Chemical Properties

• Melting Point: 164-165℃
• Boiling Point: 498.1°C at 760 mmHg
• Flash Point: 255°C
• Appearance: /
• Density: 1.165
• Vapor Pressure: 4.67E-10mmHg at 25°C
• Refractive Index: 1.6
• Storage Temp.: 2-8°C
• PKA: 15.82±0.50(Predicted)
• CAS DataBase Reference: 3-PYRIDINECARBOXAMIDE, 4-(2-METHYLPHENYL)-6-(4-METHYL-1-PIPERAZINYL)-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-PYRIDINECARBOXAMIDE, 4-(2-METHYLPHENYL)-6-(4-METHYL-1-PIPERAZINYL)-(342417-01-0)
• EPA Substance Registry System: 3-PYRIDINECARBOXAMIDE, 4-(2-METHYLPHENYL)-6-(4-METHYL-1-PIPERAZINYL)-(342417-01-0)

Safety Data

• Hazardous Substances Data: 342417-01-0(Hazardous Substances Data)

Usage

General Description

3-Pyridinecarboxamide, 4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-, also known as Trazodone, is a psychoactive drug with sedative, anxiolytic, and antidepressant properties. It is primarily used to treat depression, anxiety, and insomnia. Trazodone works by increasing the levels of serotonin in the brain, which helps to improve mood and reduce anxiety. It is often used as an alternative to other antidepressant medications due to its fewer side effects and lower risk of dependence. However, it can cause drowsiness and dizziness, so it should be taken with caution. Trazodone is typically available in the form of tablets or extended-release tablets for oral administration.

InChI:InChI=1/C18H22N4O/c1-13-5-3-4-6-14(13)15-11-17(20-12-16(15)18(19)23)22-9-7-21(2)8-10-22/h3-6,11-12H,7-10H2,1-2H3,(H2,19,23)

Upstream product

• 109-01-3 1-methyl-piperazine 
• 342417-00-9 6-chloro-4-(o-tolyl)nicotinamide 
• 881743-64-2 N-tert-butyl-6-(4-methylpiperazin-1-yl)-4-(o-tolyl)nicotinamide 
• 115309-58-5 N-tert-butyl-6-chloro-nicotinamide 
• 342416-99-3 6-chloro-4-o-tolyl-nicotinic acid 
• 342417-04-3 N-tert-butyl-6-chloro-4-(o-tolyl)nicotinamide 
• 873443-66-4 3-cyano-2,6-dichloro-4-(2-methylphenyl)pyridine 
• 529-20-4 2-methylphenyl aldehyde 
• 70625-63-7 methyl 2-cyano-3-(2-methylphenyl)-2-propenoate 
• 33252-28-7 6-chloronicotinonitrile 
• 33872-80-9 o-tolyl magnesium chloride 
• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 
• 58757-38-3 6-Chloronicotinoyl chloride 

Downstream Products

• 1431216-59-9 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium 
• 1431216-68-0 4-(5-{2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethylpropanamido}-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-{[bis(tert-butoxy)phosphoryl]oxymethyl}piperazin-1-ium 
• 1431216-61-3 1-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-4-methylpiperazine 1,4-dioxide 
• 290297-24-4 6-(4-methyl-piperazin-1-yl)-4-o-tolylpyridin-3-yl-amine 
• 342417-02-1 [6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl]carbamic acid methyl ester 
• 290297-26-6 netupitant 
• 290297-25-5 methyl-[6-(4-methyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-amine 

Relevant articles and documents

Synthesis method of 6-(4-methylpiperazine-1-yl)-4-o-tolyl nicotinamide

The invention discloses a synthesis method of 6-(4-methylpiperazine-1-yl)-4-o-tolyl nicotinamide, which comprises the following steps: (1) taking 6-chloronicotinonitrile as an initial raw material, carrying out nucleophilic addition reaction on the initial raw material and a reagent A in the presence of a boron trifluoride reagent, and after the reaction is completed, adding an oxidizing agent to carry out oxidation reaction to obtain a compound (II); the reagent A is o-tolyl magnesium halide or a combination of o-tolyl magnesium halide and lithium chloride; (2) condensing the compound (II) and N-methyl piperazine to generate a compound (III); (3) carrying out hydrolysis reaction on the compound (III) and hydrogen peroxide under the action of alkali to generate a compound (IV); the method is simple in reaction route, mild in reaction condition, high in product yield and suitable for industrial production.

4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator

Compounds and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor, based on 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)3yridine-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium and pharmaceutically acceptable salts thereof.

Substituted 4-phenyl pyridines having anti-emetic effect

Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor. The compounds have the general formula (I):